Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Hutagalung 2002 THA (Continued)<br />
5. Adverse events<br />
Not included in the review:<br />
1. Fever clearance<br />
2. Parasite clearance<br />
3. Gametocyte clearance<br />
Notes Country: Thailand<br />
Setting: Malaria clinics of the Shoklo Malaria Research Unit<br />
Transmission: Low and unstable<br />
Resistance: Multiple-drug resistance<br />
Dates: July 2001 to June 2002<br />
Funding: Wellcome Trust of Great Britain<br />
Risk of bias<br />
Item Authors’ judgement Description<br />
Adequate sequence generation? Yes ’Computerized randomisation was in<br />
blocks of ten’<br />
Allocation concealment? No None described<br />
Blinding?<br />
All outcomes<br />
Incomplete outcome data addressed?<br />
All outcomes<br />
No An open label trial. No comment on blinding<br />
of laboratory staff.<br />
Yes Losses to follow up balanced and low in<br />
both groups (8% AL6 vs 7% AS+MQ)<br />
Free of selective reporting? Yes <strong>The</strong> WHO recommends 63 days follow up<br />
in studies of AS+MQ. Day 42 outcomes<br />
may under estimate treatment failure with<br />
AS+MQ.<br />
Free of other bias? Yes No other sources of bias identified<br />
Janssens 2003 KHM<br />
Methods Trial design: An open label randomized controlled trial<br />
Follow up: Monitored daily until fever and parasites cleared then weekly to day 63.<br />
Temperature, symptom questionnaire, malaria film, and haematocrit at each visit.<br />
Adverse event monitoring: An adverse event defined as any new sign or symptom appearing<br />
after treatment started. At each visit a symptom questionnaire was completed.<br />
Participants Number: 464 randomized<br />
Inclusion criteria: Age > 1 yr, axillary temp > 37.5 ºC or history of fever, signs and<br />
symptoms of uncomplicated malaria, P. falciparum mono or mixed infections, written<br />
in<strong>for</strong>med consent<br />
Exclusion criteria: Pregnancy or lactation, signs or symptoms of severe malaria, > 4% red<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
63